DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 086065
NDA 086065 describes PROCAN SR, which is a drug marketed by Parke Davis and Parkedale and is included in four NDAs. Additional details are available on the PROCAN SR profile page.
The generic ingredient in PROCAN SR is procainamide hydrochloride. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
The generic ingredient in PROCAN SR is procainamide hydrochloride. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
Summary for 086065
| Tradename: | PROCAN SR |
| Applicant: | Parkedale |
| Ingredient: | procainamide hydrochloride |
| Patents: | 0 |
| Therapeutic Class: | Cardiovascular Agents |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 086065
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, EXTENDED RELEASE;ORAL | Strength | 500MG | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
